Pharma Wholesale and Distribution Market Report 2025-2035: Revenues will Surpass $1.03 Trillion - Opportunities in Specializing in Niche Drugs and Therapies, and Cold Chain for Specialty Pharma
Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Pharma Wholesale and Distribution Market Report 2025-2035" report has been added to ResearchAndMarkets.com's offering.
Overall world revenue for the Pharma Wholesale and Distribution Market: In terms of value the market will surpass US$ 1.03 trillion in 2025
This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Cold Chain Positions Itself as the Core of Specialty Pharma Growth
The pharmaceutical wholesale and distribution landscape is undergoing a decisive structural shift: cold chain is no longer a supportive logistics layerit has become the industry's core strategic backbone. With an expanding share of global pipelines centred on temperature-sensitive products including vaccines, biologics, cell- and gene-based therapies, and the accelerating GLP-1 class wholesalers and distributors are realigning their strategies according to the growing demand for frozen and refrigerated storage, validated packaging systems, and continuous temperature-integrity monitoring at scale.
This shift is reflected in two major 2025 announcements signalling a new phase of infrastructure modernisation. In March 2025, DHL confirmed its agreement to acquire U.S. life-science logistics specialist CryoPDP, strengthening its temperature-controlled capabilities across biopharma, advanced therapies and clinical-trial distribution. The move builds on the company's US$5.7 billion healthcare revenues in 2024, underscoring its ambition to lead global cold-chain logistics through integrated, end-to-end platforms.
On 5 November 2025, Cencora unveiled a landmark US$1 billion investment programme aimed at transforming its U.S. pharmaceutical distribution network through 2030. The initiative includes construction of a new 530,000 sq. ft national distribution centre in Harrison, Ohio, alongside major expansions in California and Alabama. These next-generation hubs will integrate advanced warehouse automation, robotic picking systems and significantly enhanced refrigerated and frozen storage capacity to support the rising flow of specialty pharmaceuticals.
For the pharma wholesale and distribution ecosystem, these developments mark a critical inflection point. The fastest-expanding therapeutic categories oncology drugs, biologics, vaccines, and GLP-1 therapies demand ultra-reliable cold-chain control and precision handling. Cencora's investment signals a recalibration of competitive advantage: wholesalers must now operate as cold-chain, automation and data-driven fulfilment specialists, not merely intermediaries in the supply chain.
The implications are clear for all players across your segmentation from branded and generic pharmaceutical distributors to vaccine, biologics, and medical-device channels. Strategic alignment with high-performance temperature-controlled logistics partners or the development of internal capabilities of comparable scale is rapidly becoming a prerequisite to securing national contracts, institutional tenders and long-term manufacturer partnerships.
As cold chain transitions into a mission-critical asset, market leaders will be defined by their ability to deliver temperature-integrity, operational resilience and technology-enabled distribution excellence across increasingly complex product portfolios.
What would be the Impact of US Trade Tariffs on the Global Pharma Wholesale and Distribution Market?
U.S. trade tariffs can significantly disrupt global pharmaceutical wholesale and distribution by increasing import costs for APIs, finished drugs, packaging materials and medical devices sourced from China, India and Europe. Higher landed costs compress distributor margins and may trigger price adjustments across branded, generic and OTC channels.
Tariffs also slow cross-border flow times, forcing wholesalers to hold larger safety stocks and invest more in working capital. For multi-party distributors and PCD/institutional suppliers, tariff volatility increases procurement risk and complicates contracting with manufacturers. Ultimately, tariffs create cost instability, supply uncertainty and operational pressure across the entire distribution ecosystem.
Key Questions Answered
Market Dynamics
Market Driving Factors
Market Restraining Factors
Market Opportunities
Leading Companies Profiled
Segments Covered in the report:
Type
Distribution Type
Product Type
End-users
Full List of Companies and Organisations Featured
For more information about this report visit https://www.researchandmarkets.com/r/tns4ky
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.